Multiple assets in pre-clinical and clinical development
| Product | Indication | Pre-clinical IIT Phase I Phase II NDA/BLA List |
|---|---|---|
| BRG01 |
Global (First-in-Class)
Nasopharyngeal cancer (NPC)EBV+ LymphomaBRG01 in NPC is granted Fast Track Designation by US FDA
|
50%
46%
|
| BRL03 |
Global (First-in-Class)
Multiple solid tumors (incl. Lung)
|
40%
|
| BST02 |
Global (First-in-Class)
Liver cancer (all types)BST02 is granted Fast Track Designation by US FDA
|
40%
|
| BGT007 |
Global (First-in-Class)
CRC, GC, EC & PDAC
|
25%
|
| Multi-specific antibodies |
Global (First-in-Class)
Multiple solid tumors
|
15%
|
| Allo-cel |
Global (First-in-Class)
Multiple solid & liquid tumors
|
15%
|
WORK WITH US
Take part in our mission to deliver more effective cancer care and
